Details of the management of the three PwHA undergoing synovectomy managed with additional prophylaxis∗
| . | Synovectomy . | Synovectomy . | Arthrofibrosis + chondroplasty + joint debridement + synovectomy . |
|---|---|---|---|
| Type of prophylaxis | SHL rFVIII | SHL rFVIII | rFVIIa |
| Cumulative dose | |||
| Preoperative | 55.0 IU/kg | 106.7 IU/kg | 170.2 μg/kg |
| Postprocedure | 192.6 IU/kg | — | 4087.8 μg/kg |
| Doses in the first 7 d postprocedure, n | 4 | — | 49 |
| Total post-op d on prophylaxis or treatment | 3 | — | 15 |
| Bleed because of surgery | No | No | Yes |
| Additional medication | — | — | — |
| AEs of special interest | No TE or TMA | No TE or TMA | No TE or TMA |
| . | Synovectomy . | Synovectomy . | Arthrofibrosis + chondroplasty + joint debridement + synovectomy . |
|---|---|---|---|
| Type of prophylaxis | SHL rFVIII | SHL rFVIII | rFVIIa |
| Cumulative dose | |||
| Preoperative | 55.0 IU/kg | 106.7 IU/kg | 170.2 μg/kg |
| Postprocedure | 192.6 IU/kg | — | 4087.8 μg/kg |
| Doses in the first 7 d postprocedure, n | 4 | — | 49 |
| Total post-op d on prophylaxis or treatment | 3 | — | 15 |
| Bleed because of surgery | No | No | Yes |
| Additional medication | — | — | — |
| AEs of special interest | No TE or TMA | No TE or TMA | No TE or TMA |
AE, adverse event; post-op, post-operative; TE, thromboembolic event; TMA, thrombotic microangiopathy.
There was 1 additional major surgical case of synovectomy, which was managed without prophylaxis.